Yuki Nishida

OncoDaily

News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary

Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me

March, 2025

Yuki Nishida

Dec 18, 2023, 12:59 | Blog

Yuki Nishida: Our research on MYC overexpression in TP53 mutant acute myeloid leukemia stem-like cells

Yuki Nishida, a Research Instructor at MD Anderson Cancer Center, shared a post by Edward…

Dec 7, 2023, 04:32 | Insight

Yuki Nishida: This is one of the continuous efforts to overcome therapy resistance in acute myeloid leukemia by enhancing the activity of p53

Yuki Nishida, Instructor at MD Anderson Cancer Center, recently shared on LinkedIn: "Our paper has…

Oct 21, 2023, 19:35 | Blog

Yuki Nishida: It was such an honor that I was able to introduce our recent work on p53/MDM2 and mutant p53.

Yuki Nishida, Instructor at MD Anderson Cancer Centre, shared on LinkedIn: “It was such an…

All: 3 Posts: 1 - 100

'

Karen Knudsen has been appointed as the CEO of the Parker Institute for Cancer Immunotherapy

'

Highlights from ELCC 2025

'

FDA Approved Pluvicto (177Lu-PSMA-617) for Metastatic Castration-Resistant Prostate Cancer

'

Meet the New AACR Board of Directores for 2025-2028 Term

'

Do Artificial Sweeteners Cause Cancer? Myths and Facts

Special Coverage

Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
ESMO 2024 Congress
September 13-17, 2024
ASCO Annual Meeting
May 30 - June 4, 2024
Yvonne Award 2024
May 31, 2024
OncoThon 2024, Online
Feb. 15, 2024
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023